{"id":113,"date":"2022-12-23T10:00:00","date_gmt":"2022-12-23T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=113"},"modified":"2025-09-01T03:57:47","modified_gmt":"2025-09-01T03:57:47","slug":"china-bd-deal-2022-kelun-biotech-and-merck-msd-enters-a-9-4-billion-usd-license-on-seven-preclinical-adcs","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2022\/113.html","title":{"rendered":"[China BD deal 2022] Kelun-Biotech and Merck\/MSD enters a 9.5 billion USD license on seven\u00a0preclinical ADCs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2022-12-22 (December 22, 2022)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset: Seven investigational preclinical ADC for the treatment of cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd, China)&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): \u00a0Merck\uff0cknown as MSD outside of the United States and Canada,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Antibody drug conjugate (ADC)&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: \u00a0Undisclosed<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: preclinical <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kelun-Biotech has granted Merck exclusive global licenses to research, develop, manufacture and commercialize multiple investigational preclinical ADC therapies and exclusive options to obtain additional licenses to ADC candidates. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kelun-Biotech retains the right to research, develop, manufacture and commercialize certain licensed and option ADCs for mainland China, Hong Kong and Macau.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deal Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of\u00a0$175 million,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Milestone payments up to \u00a0$9.3 billion,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total up to $9.475 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Merck also intends to make an equity investment in Kelun-Biotech.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.merck.com\/news\/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer\/\">https:\/\/www.merck.com\/news\/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2022-12-22 (December 22, 2022) Asset: Seven investigational preclinical ADC for the treatment of cancer. &hellip; <a title=\"[China BD deal 2022] Kelun-Biotech and Merck\/MSD enters a 9.5 billion USD license on seven\u00a0preclinical ADCs\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2022\/113.html\"><span class=\"screen-reader-text\">[China BD deal 2022] Kelun-Biotech and Merck\/MSD enters a 9.5 billion USD license on seven\u00a0preclinical ADCs<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-113","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=113"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/113\/revisions"}],"predecessor-version":[{"id":116,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/113\/revisions\/116"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}